Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor
Completed
The Medicines Company
Phase 1
2005-03-01
The purposes of this study are to:
- Evaluate the tolerability of two cangrelor regimens.
- Compare the PD of cangrelor regimens with oral clopidogrel.
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
Terminated
The Medicines Company
Phase 3
2006-04-01
The primary objective of this study is to demonstrate that the efficacy of cangrelor is
superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
Terminated
The Medicines Company
Phase 3
2006-09-01
The primary objective of this study is to demonstrate that the efficacy of cangrelor
(combined with usual care) is superior to that of usual care, in subjects requiring
percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality,
myocardial infarction (MI), and ischemia-driven revascularization (IDR).
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before
coronary artery bypass grafting have an acceptable safety profile and can undergo surgery
without excessive bleeding peri-operatively.
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
Completed
Icahn School of Medicine at Mount Sinai
Phase 2
2007-04-01
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce
ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention
(PCI).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
